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Abstract	
	
	 The	 curious	 patterns	 of	 imprinted	 gene	 expression	 draw	 interest	 from	 several	
scientific	 disciplines	 to	 the	 functional	 consequences	 of	 genomic	 imprinting.	 Methods	 of	
probing	 the	 function	 of	 imprinting	 itself	 have	 largely	 been	 indirect	 and	 correlational,	
relying	heavily	 on	 conventional	 transgenics.	Recently,	 the	burgeoning	 field	 of	 epigenome	
editing	has	provided	new	tools	and	suggested	strategies	 for	asking	causal	questions	with	
site	specificity.	This	special	report	aims	to	outline	how	these	new	methods	may	be	applied	
to	questions	of	functional	imprinting	and,	with	this	aim	in	mind,	to	suggest	new	dimensions	
for	the	expansion	of	these	epigenome-editing	tools.	
	
Key	 words:	 Epigenome	 Editing,	 EpiEffectors,	 Imprinting,	 functional	 consequences,	
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Introduction/Background	
	
Investigation	into	the	functional	consequences	of	various	epigenetic	marks	requires	
epigenome-editing	 tools,	with	 the	 capacity	 for	 specific	 targeting	and	mitotically	heritable	
modification.	 Important	 regulatory	 targets	 for	 epigenome	 editing	 include	marks	 such	 as	
methylation	at	CpG	islands,	methylation	at	differentially	methylated	regions	(DMRs–these	
exhibit	 DNA	 methylation	 asymmetry	 between	 parental	 copies),	 and	 modifications	 to	
histone	tails	(including	activating	and	repressive	methylation	and	activating	acetylation	at	
regulatory	chromatin	regions)[1].	Targets	also	 include	more	complex	configurations	such	
as	bivalent	chromatin	domains	and	changes	in	higher	chromatin	structure	[1,2].	While	we	
have	some	knowledge	of	the	effect	of	various	marks	(for	instance	that	Histone	3,	Lysine	27	
trimethylation	 (H3K27me3)	 is	 repressive),	 they	 often	 exist	 within	 a	 more	 complicated	
architecture	with	 conflicts	 and	 redundancies.	Exploring	 functional	 consequences	of	 these	
marks	at	specific	loci	requires	fine	dissection	strategies.	
	 We	restrict	our	discussion	here	to	methods	applicable	to	imprinted	genes,	which	are	
defined	by	 their	parent	of	origin	monoallelic	expression	 [3].	 Imprinting	occurs	when	one	
parental	allele	 is	epigenetically	marked	during	embryogenesis,	 creating	a	basis	 for	allele-
specific	regulatory	differences.	Germline	DMRs	on	the	parental	genomes	are	established	at	
fertilization	 and	 are	 protected	 from	 genome-wide	 demethylation	 during	 embryogenesis	
[1].	 These	 differences	 are	 reiterated	 with	 further	 modifications	 in	 later	 developmental	
stages	to	elaborate	and	maintain	the	imprinting	mark	[4].	The	minimal	region,	as	defined	
by	 targeted	deletions,	which	regulates	an	 imprinted	 locus	 is	 termed	an	 imprinting	centre	
(IC)	or	 imprinting	control	 region	 (ICR)	 [4].	While	 some	 ICRs	regulate	 imprinted	domains	
extending	 over	 large	 regions	 of	 DNA	 and	 require	 complex	 and	 extensive	 epigenetic	
architecture	 to	 regulate	 a	 cluster	 of	 genes,	 others	 regulate	 a	 single	 imprinted	 protein-
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coding	 gene	 [5,6].	 Furthermore,	 imprinting	 architecture	 can	 vary	 between	 tissues	 and	
developmental	 stages,	 resulting	 in	 differing	 expression	 patterns	 in	 abundance	 and	 splice	
variants.	This	variation	is	the	result	of	tissue-	and	stage-specific	epigenetic	modification	at	
the	 locus	and	 is	 subsequently	maintained	 through	several	 rounds	of	DNA	replication	 [4].	
The	 long-term	 maintenance	 of	 these	 marks	 is	 an	 important	 element	 for	 qualifying	
imprinting	architecture	as	epigenetic	rather	than	simply	regulatory	and	will	be	important	
in	the	assessment	of	epigenome	editing	tools	we	consider	for	functional	research.		
There	are	approximately	120-180	imprinted	genes	identified	in	the	mouse,	and	around	
100	 in	 humans	 [7].	While	 these	 genes	 do	 not	 appear	 to	 associate	 within	 any	 particular	
biochemical	pathway,	thematic	phenotypic	and	physiological	consequences	do	emerge.	Of	
these,	 the	most	 prominent	 are	 functions	within	 the	 embryo,	 extra-embryonic	 tissue,	 and	
the	adult	central	nervous	system	[7,	8].	 	Imprinted	genes	have	a	role	in	placental	size	and	
function,	 in-utero	 growth,	 nutrient	 transport,	 and	 placental	 signalling	 [9,10,11].	 In	
metabolic	systems,	 imprinted	genes	have	a	role	 in	prenatal	growth,	appetite,	 fat	and	 lean	
mass	deposition,	energy	homeostasis,	and	insulin	sensitivity	and	production	[9].	Imprinted	
gene	expression	is	particularly	prominent	in	the	central	nervous	system	and	in	addition	to	
diverse	behavioural	associations	-	 including	maternal	care	and	mother-infant	interactions	
[12,	 13,	 14,	 7],	 social	 dominance	 [15,	 16],	 and	 exploration	 [15,17]	 -	 there	 is	 growing	
association	with	neuropsychiatric	and	neurodevelopmental	disorders	[3,18,	19].	
	
Conventional	Transgenic	Strategies		
	
	 Thus	 far,	 we	 have	 determined	 the	 functional	 consequence	 of	 imprinting	 without	
control	of	specific,	localized	marks.	In	fact,	most	studies	examine	the	degree	of	association	
between	imprinted	regions	and	disease	or	disorder	[3,	19]	and/or	the	function	of	the	genes	
within	imprinted	regions,	rather	than	the	imprint	itself.		
	 Knockout	 models	 are	 a	 classic	 starting	 point	 used	 in	 many	 functional	 studies	 of	
imprinting.	 These	 models	 often	 delete	 only	 one	 allele,	 making	 use	 of	 the	 monoallelic	
expression	patterns	to	demonstrate	the	function	of	both	the	gene	and	its	requisite	origin.	
For	 example,	 loss	 of	 function	 of	 the	 maternal	 Phlda2	 allele	 resulted	 in	 an	 expanded	
placental	 spongiotrophoblast	 compartment	 and	 dysregulated	 placental	 hormones	 [20].	
While	these	approaches	are	useful	in	distinguishing	the	function	of	allele	origin,	they	often	
result	 in	 broad	 loss	 of	 gene	 function,	 rather	 than	 providing	 insight	 into	 the	 inner	
mechanisms	of	imprinting	or	the	fine	control	it	exerts	in	an	endogenous	setting	[21].		
Loss	 of	 imprinting	 (LOI)	 KO	 models	 may	 reveal	 different	 and	 somewhat	 more	
specific	 functional	 effects	 by	 interrupting	 or	 deleting.	 Precise	 placement	 of	 these	
interruptions	 and	deletions	 can	 reveal	more	detailed	knowledge	of	 imprint	 function.	 For	
instance,	 interruption	 of	 the	 maternally	 inherited	 Gtl2	 promoter	 by	 insertion	 of	 a	 ßgeo	
cassette	 upstream	 created	 a	 partial	 loss	 of	 imprinting	which	 shifted	 transcript	 dosage	 in	
the	 chromosome	12	 imprinted	 gene	 cluster	 from	maternal	 expression	 towards	 paternal-
origin	 expression	 patterns	 [22].	 LOI	 models	 may	 also	 distinguish	 the	 function	 of	 the	
somatic	 (established	 during	 development	 and	 cellular	 differentiation)	 or	 germline	
(established	prior	to	fertilization)	ICRs.	Whereas	deleting	a	germline	IC	may	eliminate	the	
imprinting	mark	altogether,	deletion	of	a	somatic	IC	can	reveal	the	tissue-specific	roles	of	
certain	epigenetic	architectures	regulating	gene	dosage	at	critical	stages	[4].		
Duplication	 of	 imprinted	 regions	 provides	 another	 method	 for	 functional	
investigation,	 mimicking	 the	 effects	 of	 LOI	 at	 one,	 or	 a	 cluster	 of	 imprinted	 genes.	
Uniparental	 disomies	 and	 duplications	 of	 the	 imprinted	 chromosomal	 region	 are	
particularly	useful	 in	characterizing	the	phenotypes	of	 increased	dosage	[21].	Transgenes	
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are	useful	 tools	 for	 introducing	duplication.	For	 instance,	 the	addition	of	an	extra	copy	of	
maternally	 expressed	 Phlda2	 carried	 by	 a	 bacterial	 artificial	 chromosome	 (BAC)	
significantly	reduced	placental	weight,	demonstrating	a	purpose	in	growth	restriction	[23].	
Additionally,	it	is	possible	to	normalize	expression	levels	and	thereby	rescue	these	models,	
by	 crossing	with	a	 targeted	deletion	model	 [24].	Various	 types	of	 transgenes	 can	also	be	
used	to	define	the	regional	specificity	of	ICRs	and	to	dissect	the	functional	consequences	of	
imprinted	regions	regulating	multiple	genes	[21].	These	duplication	strategies	still	rely	on	
the	endogenous	organization	of	 ICRs	and	the	genomic	sequences	they	regulate.	However,	
they	 still	 duplicate	 the	 coding	 genome	 sequences	 themselves.	 One	 way	 to	 separate	 the	
function	of	the	imprinting	centre	from	the	genes	it	regulates	is	the	insertion	of	a	reporter	
gene	 near	 the	 ICR.	 Exogenous	 sequences	 inserted	within	 known	 imprinted	 regions	 have	
been	shown	to	acquire	 functionally	relevant	epigenetic	 imprints	 following	 the	 imprinting	
pattern	of	the	targeted	locus	[25,	26].	Inserted	elements	can	also	interact	with	long	range	
imprinting	 signals	 on	 their	 own	 to	 generate	 a	 new	 imprinted	 locus	 with	 tissue-specific	
imprinted	expression	patterns	[27].	These	instances	create	a	useful	model	for	studies	of	the	
evolutionary	 origin	 of	 and	 function	 of	 imprinted	 gene	 clusters.	 An	 example	 is	 the	 novel	
transgenic	mouse	 line	Tel7KI	 (Instm1Lef),	expresses	 the	 fluorescent	reporter	EGFP	 from	an	
inserted	 transgene	 located	on	Chromosome	7	between	 the	 imprinting	centre	1	 (IC1)	and	
imprinting	 centre	 2	 (IC2)	 regions	 [27].	 This	 insert	 gained	 maternal	 allele-specific	
expression	 specifically	 in	 embryonic	 tissues	 while	 remaining	 biallelic	 in	 placenta.	 The	
authors	suggest	 this	as	a	model	 for	how	novel	genes	become	imprinted	during	evolution.	
The	 tool	 also	 provides	 a	 strategy	 for	 dissecting	 epigenetic	 differences	 between	 tissue	
lineages	 and	 for	 interpreting	 the	 functional	 consequences	 of	 imprinting	 signals,	
independent	of	endogenous	genes.		
	 	
A	 drawback,	 and	 potentially	 confounding	 factor	 in	 all	 these	 models,	 is	 the	 direct	
manipulation	of	the	genetic	material	near	the	ICR.	Strategies	circumventing	this	disrupt	the	
endogenous	epigenetic	mark	or	 imprinting	mechanism.	For	 instance,	deletion	of	essential	
endogenous	effectors	such	as	DNA	methyltransferase	(Dnmt1,	not	imprinted)	prevents	the	
establishment	 or	 maintenance	 of	 the	 imprinting	 mark	 [28].	 However,	 this	 approach	 is	
unspecific	to	the	locus	of	interest	and	may	create	widespread	changes	across	the	genome,	
dysregulating	 many	 genes	 and	 obscuring	 the	 resulting	 LOI	 phenotype	 [21].	 	 Equally,	
pharmacological	removal	of	a	mark	using	agents	such	as	5-azacytidine	(demethylation)	has	
widespread	rather	than	specific	effects,	obscuring	functional	consequences	of	disruption	of	
imprinting	 [29,	 30].	 	 Deletion	 of	 epigenetic	 marks	 by	 these	 methods	 can	 show	 their	
necessity	 for	 normal	 imprinting,	 but	 are	 likely	 to	 obscure	 the	 specific	 functional	
consequence	of	such	a	mark.	While	association,	knockout,	and	pharmacological	studies	are	
very	helpful	 for	discerning	 the	broader	 impact	of	 imprinting	on	biological	 systems,	 these	
strategies	fall	short	of	the	high	resolution	needed	to	probe	the	function	of	imprinting	marks	
independent	of	the	genetic	sequence	beneath	them	
	
Tools	for	Targeted	Epigenome	Editing	
	
	 Tools	 for	 targeted	 epigenome	 editing	 could	 allow	 researchers	 to	 probe	 functional	
consequences	 of	 imprinting	 by	 manipulating	 regulatory	 marks	 themselves,	 without	
changing	genomic	content.	This	may	enable	us	 to	ask	more	specific	and	causal	questions	
about	the	function	of	imprinting.	Epigenome	engineering	can	break	down	and	reconstruct	
heritable	 regulatory	 architecture	 and	 build	 it	 ectopically	 to	 discern	 both	 the	 function	 of	
individual	parts	and	the	synergistic	functional	consequences	of	imprinting	structures.	
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	 The	 basic	 structure	 of	 an	 EpiEffector,	 or	 epigenome	 engineering	 tool,	 is	 a	
programmable	DNA	binding	domain	(DBD)	or	mechanism	coupled	to	an	epigenetic	effector	
domain.	 Popular	 binding	 domains	 include	 zinc	 finger	 nucleotides	 (ZFNs),	 transcription	
activator-like	 effector	 (TALE)	 nucleases,	 and	 the	 clustered	 regularly	 interspaced	 short	
palindromic	repeats/nuclease	deficient-Cas9	(CRISPR/dCas9)	system.	A	 figure	comparing	
binding	domains	and	an	extensive	table	of	possible	epigenetic	effector	domains	and	can	be	
found	in	Laufer	2015	[31].	An	elegant	diagram	of	an	example	EpiEffector	may	be	found	in	
Vojta	2016,	and	is	included	in	this	article	as	Figure	1	[32].	This	report	focuses	on	CRISPR	
based	 tools	because	of	 the	ease	and	multiplexing	capacity	of	 targeting	by	synthetic	guide	
RNAs	(sgRNAs)	compared	to	the	more	difficult	design	process	of	ZFNs	and	TALE.	However,	
all	 types	 of	 EpiEffector	 are	 applicable.	 CRISPR-based	 tools	 specifically	mentioned	 in	 this	
report	are	summarized	in	Table	1.		
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Figure	 1	 –	Anatomy	 of	 Example	 CRISPR/dCas9–based	 EpiEffector:	 dCas9-DNMT3A
	
Figure	1	Legend:		
	
(A)	The	dCas9-DNMT3A	fusion	protein	complexes	with	the	sgRNA	(composed	of	the	fused	
crRNA	or	guide	RNA	and	tracrRNA)	to	target	the	DNMT3A	effector	domain	to	the	target	
region.	The	dCas9	segment	is	composed	of	a	recognition	lobe	(Rec	I,	II,	and	III)	and	an	
inactivated	nuclease	lobe	(HNH,	RuvC,	and	PI	domains).	The	DNMT3A	effector	is	fused	to	the	
PAM-interacting	(PI)	domain	on	the	nuclease	lobe	by	a	nuclear	localization	signal	(NLS)	and	
a	Gly4Ser	(GS)	peptide	linker.	The	DNMT3A	catalytic	domain	recruits	partners	for	
dimerization	to	carry	out	targeted	methylation.	
(B)	 Linear	 order	 of	 domains	 on	 the	 dCas9-DNMT3A	 fusion	 protein.	 The	 N-terminal	 begins	
with	 the	 3x	 FLAG	 epitome	 tag	 and	 the	 nuclear	 localization	 signal	 (NLS),	 followed	 by	 the	
nuclease-inactivated	 deactivated	 Cas9	 (dCas9)	 domain	 (inactivating	 mutations	 D10A	 and	
H840A	ARE	INDICATED).	dCas9	 is	 followed	by	a	second	NLS,	and	a	GS	peptide	 linker	which	
fuse	it	to	the	catalytic	domain	of	human	de	novo	DNA	methylatransferase	3A	(DNMT3A	CD).	
In	 this	 domain,	 E155A	 indicates	 the	 DNMT3A	 inactivating	 mutation	 used	 as	 a	 negative	
control.	 The	 mRNA	 for	 this	 fusion	 protein	 also	 contains	 a	 puromycin	 resistance	 gene	
transcript	 (protein	 domain–PuroR)	 or	 EGFP	 gene	 (not	 shown)	 for	 selection	 of	 successfully	
transfected	 cells.	 During	 translation,	 this	 selector	 separates	 from	 the	 EpiEffector	when	 the	
T2A	self-cleaving	peptide	detaches	the	fusion	protein’s	C	terminal	end.	
Perspectives	
	 6	
Table	1	–	CRISPR	based	tools	in	this	report	
	
	
	 Two	 recently	 published,	 simple	 CRISPR-based	 EpiEffectors	 direct	 the	 addition	 of	
fundamental	 histone	 marks.	 The	 dCas9-p300(core)	 tool	 from	 Hilton	 2015	 permits	 the	
targeted	 addition	of	 the	 activating	histone	3,	 lysine	27	 acetylation	 (H3K27ac)	mark	 [33].	
H3K27ac	was	used	here	as	a	relative	measurement	of	broad	p300	acetyltransferase	activity	
and	a	widely	documented	indicator	of	enhancer	activity.	This	tool	causally	linked	target	site	
enrichment	 of	H3K27ac	with	 highly	 specific	 target	 gene	 activation	 at	 levels	 greater	 than	
those	 induced	 by	 the	 conventional	 engineered	 transactivator	 dCas9-VP64	 [34].	 When	
targeted	to	DNase	I	hypersensitive	site	2	(the	HS2	enhancer)	on	the	mammalian	β-globin	
locus	 control	 region	 (not	 imprinted)[35],	 this	 construct	 was	 also	 more	 effective	 than	
dCas9-VP64	at	enriching	H3K27ac	at	distal	promoters	regulated	by	the	HS2	enhancer	[33].	
The	 effect	 of	 this	 construct	 provides	 evidence	 the	 histone	 acetylation	 it	 catalyses	 is	 a	
sufficient	modification	for	inducing	enhancer	activity.	Hilton	et	al	use	the	dCas9-p300(core)	
tool	to	systematically	dissect	the	histone	regulatory	modifications	necessary	for	expression	
at	 targeted	 regulatory	 regions,	 but	 tools	 such	 as	 this	 could	 be	 similarly	 employed	 to	
demonstrate	 the	 histone	 marks	 sufficient	 for	 inducing	 the	 expression	 patterns	 of	
imprinting.	
The	 CRISPR/dCas9	 tool	 from	 Vojta	 2016	 uses	 the	 catalytic	 domain	 of	 DNA	
methyltransferase	DNMT3A	to	add	repressive	DNA	methylation	marks	[32].	This	achieved	
targeted	CpG	methylation	in	an	approximately	35	base	pair	wide	region,	and	multiplexing	
sgRNAs	expanded	 the	 region	of	de	novo	methylation.	The	 study	 targeted	 the	CpG	 islands	
within	the	promoter	regions	of	IL6ST	and	BACH2	(neither	imprinted),	genes	relevant	for	N-
glycosylation	of	 immunoglobulin	G	 (IgG)	and	associated	with	some	autoimmune	diseases	
[35,	36].	Expression	changes	from	these	genes	following	targeted	CpG	methylation	provide	
proof	 of	 concept	 for	 targeted	 dosage	 control	 by	 epigenome	 editing.	 IL6ST	 in	 particular	
showed	more	 than	2	 fold	 decrease	 in	 transcript	 level.	Moreover,	 changes	 in	methylation	
were	heritable	across	mitotic	divisions	up	to	42	days	after	transfection.	Such	heritability	of	
regulatory	modifications	created	by	EpiEffectors	is	crucial	to	explorations	of	the	functional	
consequences	 of	 imprinting.	 To	 properly	mimic	 true	 epigenetic	 change	 and	 reveal	 long-
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term	 developmental	 consequences,	 the	 mark	 must	 be	 long	 lasting	 and	 maintainable.	 In	
theory,	application	of	the	dCas9-DNMT3A	tool	to	ICRs	could	engineer	epigenetically	driven	
dosage	control	that	avoids	changes	to	endogenous	genomic	sequence	or	the	introduction	of	
transgenes.		
Use	 of	 a	 catalytically	 inactive	 DNMT3A	 domain	 in	 the	 Vojta	 et	 al	 construct	 still	
created	 low	levels	of	methylation	activity	at	 the	target	[32].	This	suggests	the	EpiEffector	
recruits	cell-endogenous	 interaction	partners	with	effector	activity.	EpiEffectors	need	not	
act	 exclusively	 to	 add	 and	 remove	 regulatory	 marks	 from	 the	 loci	 of	 interest,	 but	
attribution	 of	 any	 functional	 consequences	must	 acknowledge	 the	 full	 contextual	 change	
induced	 by	 targeting	 the	 EpiEffector	 to	 the	 site.	 For	 example,	 changes	 in	 regulatory	
imprinting	 marks	 at	 the	 Prader-Willi	 Syndrome	 Imprinting	 Centre	 (PWS-IS)	 could	
dysregulate	the	noncoding	C/D	box	small	nucleoloar	RNA	clusters	(SNORDs)	within	region	
15q11.2-q13	 [37].	 One	 of	 these	 clusters,	 encoding	 SNORD116,	 changes	 the	 expression	 of	
over	200	genes	when	overexpressed	 in	HEK293T	culture.	Changing	marks	regulating	 the	
imprinted	 expression	 pattern	 of	 this	 small	 nucleoloar	 RNA	 (snoRNA)	 could	 create	 a	
cascading	effect	on	gene	expression	that	conceals	the	immediate	effect	of	the	experimental	
manipulation.	However,	while	recruitment	of	endogenous	mechanisms	might	obscure	the	
effect	 of	 individual	marks,	 especially	 if	 additional	marks	 are	 altered	 or	 other	 regulatory	
agents	 are	 affected,	 it	 is	 likely	 these	 joint	 changes	will	 better	mimic	 imprinting	 patterns	
than	simple	changes	added	one	by	one.	
	
However,	 in	 the	 absence	 of	 a	 single,	 cascading	 change	 establishing	 full	 imprinting	
functions,	 researchers	must	 consider	 the	use	of	multiple	EpiEffectors	 to	break	down	and	
construct	 complex	 regulatory	 architecture.	 The	 systematic	 breakdown	 of	 epigenetic	
architectures	 can	 demonstrate	 the	 minimum	 points	 at	 which	 regulatory	 marks	 attract	
these	 secondary	 modification	 and	 maintenance	 enzymes.	 Coordinated	 changes	 may	 be	
necessary	to	discern	the	synergistic	function	of	imprinting	structures.	
	
Precise	Control	of	EpiEffector	Activity	
	
We	can	make	further	use	of	the	genome	editing	toolbox	by	taking	advantage	of	systems	for	
precise	control	of	timing.	Adding	tissue	or	stage	specific	promoters	can	trigger	EpiEffector	
expression	 within	 specific	 cellular	 contexts,	 while	 cre-loxP	 recombination	 systems	 can	
eliminate	 stably	 integrated	 EpiEffector	 expression	 after	 specific	 time	 points,	 as	 in	
traditional	 strategies	 [38].	 For	 more	 direct	 access,	 engineered	 mechanisms	 can	 use	
optogenetics	 to	 drive	 EpiEffector	 activity	 with	 high	 spatial	 and	 temporal	 specificity.	 An	
example	 of	 such	 an	 optogenetic	 actuator	 is	 the	 light-inducible	 transcriptional	 effectors	
(LITEs)	employed	in	Konermann	2013	to	drive	transcriptional	effectors	[39].	Konermann	
et	al	suggested	using	this	LITE	system	with	a	range	of	successful	TALE-histone	epigenetic	
effector	 fusions	 (epiTALES),	 constructed	 for	 repression	 of	 Glutamate	 Metabotropic	
Receptor	 2	 (Grm2,	 not	 imprinted)	 and	 a	 neural	 lineage-specifying	 transcription	 factor,	
Neurogenin	 2	 (Neurog2,	 not	 imprinted),	 in	 primary	 neurons.	 Chromatin	
immunoprecipitation	 confirmed	 epiTALE-mediated	 modification	 of	 histone	 marks	
including	H3K9me1,	H4K20me3,	H3K27me3,	H2K9ac,	and	H4K8ac.	LITE	mediated	Neurog2	
expression	 rose	 30	minutes	 after	 initial	 optogenetic	 stimulation.	Modification	 of	 histone	
marks	 could	 occur	 more	 quickly	 than	 this	 transcriptional	 output.	 Additionally,	 the	
reversibility	of	 the	conformational	 changes	 that	activate	 the	LITE	system	enables	precise	
control	of	editing	functions	within	a	narrow	temporal	window.		
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	 Optogenetics	 has	 also	 been	 employed	 in	 light-activated	 CRISPR-Cas9	 effector	
(LACE)	 systems	 to	 create	 dynamic	 and	 spatially	 specific	 transcriptional	 effectors	 (or	
transactivators)	 [40].	 Polstein	 and	 Gersbach	 describe	 the	 fusion	 of	 parts	 of	 the	 light-
inducible	 heterodimerizing	 proteins	 CRY2	 (full	 length:	 CRY2FL)	 and	 CIB1	 (N-terminal	
fragment:	CIBN)	to	transactivation	domain	VP64	(CRY2FL-VP64)	and	dCas9	(CIBN-dCas9-
CIBN)	respectively.	This	LACE	system	produced	a	high	level	of	transcriptional	activation	in	
some	cases	comparable	to	that	observed	with	constitutively	active	dCas9-VP64.	Under	this	
system,	gene	expression	response	levels	were	sensitive	to	sequential	delayed	illumination,	
light	 removal,	 and	 reillumination.	 Expression	 from	 an	 eGFP	 plasmid	 reflected	 arbitrary	
illumination	 patterns	 projected	 onto	 cell	 culture	 through	 a	 photomask,	 demonstrating	 a	
high	degree	of	spatial	precision.	LACE	systems	demonstrate	the	re-targetable	flexibility	of	
the	 CRISPR/dCas9	 system	 is	 compatible	 with	 light-induced	 recruitment	 of	 effector	
domains.	 This	 system	 could	 be	 tested	 with	 epigenetic	 effector	 domains	 to	 achieve	 fine	
control	over	imprinting	architectures	throughout	developmental	stages	in	model	systems.		
	
Potential	 Epigenome	 Engineering	 Strategies	 for	 Probing	 the	 Functional	
Consequences	of	Imprinting		
	
	 As	with	genome	editing	approaches,	epigenome	engineering	strategies	can	use	the	
‘necessary	and	sufficient’	principle	to	investigate	the	functional	consequences	of	imprinting	
architecture.	 The	 precise	 addition	 or	 removal	 of	 a	 regulatory	 mark	 can	 reveal	
consequences	for	transcription.	Changes	in	gene	dosage	as	a	whole	or	by	allele-	and	tissue-
specific	transcriptional	variants	and	protein	production	reveal	the	function	of	imprinting	in	
maintaining	differential	 usage	patterns.	 Ectopic	 expression	 at	 the	 removal	 of	 a	mark	 can	
demonstrate	a	 role	 in	 tissue-	or	stage-specific	gene	expression,	and	resulting	phenotypes	
provide	 insight	 into	 the	 importance	 of	 the	 targeted	 imprinting	 mark	 development	 or	
homeostasis.		
	
	 Ectopic	 duplication	 of	 an	 epigenetic	 mark	 or	 even	 a	 full	 imprinting	 architecture	
within	 a	 different	 tissue	 or	 developmental	 stage	 can	 demonstrate	 the	 sufficiency	 of	 that	
mark	 or	 architecture	 for	 reproducing	 precise	 expression	 patterns.	 Reproduction	 of	 this	
structure	 on	 a	 new	 genetic	 locus	 could	 also	 demonstrate	 whether	 the	 function	 of	 the	
imprint	 is	 independent	 from	 the	 surrounding	 genomic	 sequence	 or	 requires	
complementary	genetic	sequences	to	promote	or	suppress	gene	expression.		
	
	 The	timing	and	duration	of	our	modifications	will	also	affect	resultant	phenotypes.	
Mitotically,	if	not	meiotically,	heritable	marks	added	by	EpiEffectors,	as	in	Vojta	2016,	allow	
us	 to	 investigate	 downstream	 developmental	 effects	 and	 are	 especially	 important	 for	
questions	 concerning	 germline	 DMRs	 and	 imprinting	 marks	 that	 diverge	 between	
developing	 tissues.	We	 can	 use	 the	 addition	 of	 a	 stable	mark	 and	 its	 temporally	 precise	
removal	 to	define	 a	 clear	developmental	window	 in	which	 specific	 imprinting	marks	 are	
necessary	 for	 normal	 development.	 Tissue-	 or	 stage-specific	 promoters	 or	 optogenetic	
drivers	 of	 EpiEffector	 expression	 can	 provide	 this	 precise	 control	 of	 timing	 both	 in	 vitro	
and	in	vivo	[39].			
	
	 Conversely,	we	can	create	or	observe	an	epigenetic	mark	or	 imprinting	deficiency	
and	attempt	to	rescue	the	model	by	temporally	precise,	targeted	epigenetic	re-engineering	
at	 the	 ICR.	 If	we	 can	 restore	normal	 expression	by	 recreating	 the	 series	of	modifications	
that	 establish	 and	 maintain	 an	 imprinting	 mark,	 we	 can	 demonstrate	 which	 marks	 are	
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sufficient	 to	 establish	 characteristic	 expression	 patterns.	 These	 modifications	 require	
temporal	precision	to	identify	their	necessary	order	and	duration	of	relevance	during	the	
establishment	 and	 maintenance	 of	 imprinting.	 Such	 reconstructions	 may	 also	 reveal	
functional	redundancies	of	several	marks	in	the	normal	imprint	architecture.		
	
Future	Perspective:	Potential	Tools	
	
	 One	of	the	issues	of	current	methods	of	epigenome	editing	for	imprinted	genes	is	the	
lack	of	allele	specific	activity.	Global	demethylation	by	pharmaceutical	means	or	by	deletion	
of,	 for	 instance,	 a	 DNMT,	 removes	 the	 DMR	methylation	 on	 one	 allele	 that	 distinguishes	
between	them.	While	allele-specific	EpiEffector	targeting	has	been	suggested	through	SNP	
differences	in	the	sgRNA	targeting	mechanism	of	the	CRISPR/dCas9	system,	this	relies	on	
sufficient	 differences	 between	 alleles	 and	 binding	 fidelity	 [41].	 Nevertheless,	 successful	
allele-specific	 genome	editing	using	 the	CRISPR-Cas	 system	 in	 vivo	 suggests	 this	 strategy	
could	 also	 be	 viable	 for	 epigenome	 editing	 [42].	 In	 Cas9/gRNA-injected	 F344xDA	hybrid	
embryos	heterozygous	for	coat	colour	alleles	of	the	Tyr	gene	(not	imprinted),	SNP-specific	
gRNAs	 targeted	 induced	 mutations	 only	 within	 their	 respective	 alleles.	 Targeting	 the	
recessive	allele	resulted	in	6	mutations	in	21	pups	born	while	targeting	the	dominant	allele	
resulted	 in	 7	mutations	 in	 23	 pups	 born	 and	 thereby	 changed	 the	 dominant	 coat-colour	
phenotype	of	these	mutated	pups.		
Current	strategies	of	epigenome	engineering	by	EpiEffectors	have	not	yet	addressed	
the	 possibility	 of	 instead	 building	 upon	 the	 distinguishing	 methylation	 mark	 to	 achieve	
allele-specific	 regulatory	 changes	 (See	 Box	 1).	 Methylation-sensitive	 EpiEffector	 binding	
could	 be	 achieved	 by	 adding	 a	 methylation-sensitive	 domain	 with	 a	 conformational	
inhibition	of	dCas9	binding	or	of	effector	domain	activity.		
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Box	1:	Model	Epigenome	Engineering	of	the	Grb10	CGI2	Bivalent	Chromatin	Domain	
	
Epigenome	 engineering	 strategies	 building	 on	 existing	 allelic	 differences	 present	 more	
options	 for	 addressing	 complex	 architectures	 such	 as	 bivalent	 chromatin	 domains.	 The	
manipulation	 of	 histone	 modifications	 in	 an	 allele-specific	 manner	 could	 be	 used,	 for	
example,	 to	 ectopically	 resolve	 the	 Grb10	 bivalent	 chromatin	 domain	 regulating	 the	
neuron-specific	 transcript	 in	 a	 non-neuronal	 tissue	 [2].	 This	 resolution	 could	 provide	
causal	demonstration	of	the	function	of	such	marks	in	regulating	transcript	expression	and	
help	 identify	 functional	 and	phenotypic	 changes	 resulting	 from	ectopic	 resolution	of	 this	
imprinting	mark.		
From	 early	 developmental	 stages	 onwards	 through	 adult	 non-neuronal	 tissues,	
Grb10	promoters	at	the	imprinted	CpG	Island	2	(CGI2)	DMR	are	silent	on	both	alleles	[2].	A	
bivalent	chromatin	domain	featuring	both	permissive	and	repressive	histone	modifications	
characterizes	the	paternal	allele	in	these	tissues.	However,	upon	commitment	to	a	neuronal	
lineage,	 the	paternal	enrichment	 for	 the	repressive	H3K27me3	mark	 is	 lost.	The	bivalent	
chromatin	domain	is	resolved,	leaving	the	activating	H3K4me2	at	the	site.	This	removal	of	
H3K27me3	is	unlikely	to	trigger	expression	from	CGI2	on	its	own.	Tissue-specific	promoter	
reactivation	may	rely	on	neuron-specific	 factors	to	 induce	the	observed	increase	of	H3K9	
and	H3K27	acetylation	at	the	site	upon	differentiation.	
	 Current	 evidence	 for	 the	 model	 relies	 on	 correlations	 between	 histone	 mark	
enrichment	 and	 repression	 or	 expression	 of	 the	 paternal-specific	 transcripts	 originating	
from	CGI2.	Epigenome	engineering	strategies	could	provide	causal	evidence	for	this	model	
of	 Grb10	 expression	 by	 ectopically	 replicating	 this	 sequence	 of	 histone	 modifications.	
Removal	 of	H3K27me3	would	 require	 only	 a	 standard	EpiEffector	 (using,	 for	 instance,	 a	
dCas9	targeting	system	and	the	active	domain	of	 JMJD3,	an	H3K27	demethylase	[31,	43])	
localized	 to	 the	 CGI2	 locus	 sequence;	 binding	 to	 the	 paternal	 allele	 achieves	 the	 desired	
effect	and	binding	to	the	maternal	allele	does	nothing,	as	there	is	no	H3K27me3	to	remove.	
Any	 interference	 with	 or	 recruitment	 of	 endogenous	 proteins,	 which	 may	 induce	 an	
unexpected	change	at	the	maternal	site,	should	be	ruled	out	by	testing	a	control	EpiEffector	
with	 a	 catalytically	 inactive	 effector	 domain.	 Successful	 epigenome	 engineering	 here	
homogenizes	the	status	of	the	H3K27	mark	on	both	alleles.	Addition	of	the	acetyl	groups,	
on	the	other	hand,	requires	parent-of-origin	specific	modification.	A	methylation-sensitive	
EpiEffector	 could	bind	 exclusively	 to	 the	unmethylated	paternal	 CGI2	without	 relying	 on	
distinguishing	 SNPs	 to	 add	 H3K9ac	 and	 H3K27ac	 monoallelically.	 Any	 resulting	
reactivation	 of	 the	 CGI2	 DMR	 promoters	 would	 demonstrate	 the	 sufficiency	 of	 these	
combined	 histone	 modifications	 for	 inducing	 tissue-	 and	 parent-of-origin	 specific	
expression.	
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Figure	2	–	Model	of	Ectopic	Resolution	of	 the	Grb10	 Imprinting	Architecture	by	Epigenome	
Engineering	
	
	
Figure	2	Legend:	
The	 default	 state	 of	 the	 imprinted	 Grb10	 CpG	 Island	 2	 locus	 is	 characterized	 by	 repressive	
DNA	 methylation	 and	 histone	 marks	 on	 the	 maternally	 inherited	 allele	 and	 a	 bivalent	
chromatin	 domain	 on	 the	 paternally	 inherited	 allele.	 The	 bivalent	 chromatin	 domain	 is	
resolved	when	 the	 repressive	H3K27me3	mark	 is	 lost	 during	 normal	 neural	 differentiation.	
Further	on	in	differentiation,	and	likely	as	a	result	of	neuron-specific	factors,	the	site	acquires	
increased	H3K9	and	H3K27	acetylation–both	activating	marks.	Epigenome	Editing	could	be	
employed	 to	attempt	ectopic	resolution	of	 the	bivalent	chromatin	domain	and	 to	mimic	 the	
construction	 of	 the	 activating	 architecture.	 In	 this	 model,	 a	 methylation	 insensitive	
EpiEffector	 with	 H3K27me3	 demethylation	 activity	 targeted	 to	 the	 site	 could	 resolve	 the	
bivalent	 domain,	 without	 effect	 on	 the	maternal	 allele.	 This	 is	 followed	 by	 treatment	 with	
methylation-sensitive	 EpiEffectors	 possessing	 H3K9	 and	 H3K27	 acetylation	 activity.	 These	
bind	in	an	allele-specific	manner	to	the	unmethylated	paternal	allele	to	reconstruct	a	neuron-
specific	histone	profile	in	non-neuronal	tissues.	
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	 Modifications	 to	 existing	 EpiEffector	 components	 could	 improve	 multiplexing	
capacity	 as	 well	 as	 temporal	 and	 spatial	 specificity.	 CRISPR/Cas9	 systems	 have	
demonstrated	 synergistic	 effects	 through	multiplexing,	 as	 in	 Vojta	 2016	 [32]	 and	 Perez-
Pinera	2013	[34].	This	capacity	can	be	further	expanded	by	simultaneously	using	systems,	
such	as	TALEs	and	ZFNs,	with	entirely	different	targeting	strategies.	This	relieves	the	basic	
guide	 system	 from	 the	 difficulties	 of	 carrying	 multiple	 bulky	 domains	 and	 introduces	
increased	specificity	by	requiring	two	separate	systems	to	localize	to	the	correct	locus	for	
complex	editing.	The	use	of	multiple	systems	also	allows	separate	EpiEffector	domains	to	
localize	to	an	ICR,	yet	remain	autonomous,	without	risk	of	cross	targeting	by	interactions	
with	the	other	guide	system.	For	instance,	Cpf1,	a	CRISPR-associated	two-component	RNA-
programmable	 DNA	 nuclease,	 provides	 a	 smaller,	 simpler	 system	 that	 could	 replace	 or	
complement	 Cas9	 [44,	 45].	 In	 particular,	 differences	 between	 the	 shorter	 Cpf1	 guide	
CRISPR	 RNAs	 (crRNAs)	 and	 the	 analogous	 Cas9	 sgRNAs	 that	 guide	 binding	 also	 enable	
different	 EpiEffectors,	 separately	 guided	 by	 either	 Cpf1	 or	 Cas9	 systems,	 to	multiplex	 in	
close	proximity.	Finally,	arrays	of	EpiEffectors	triggered	by	optogenetic	drivers	stimulated	
by	different	wavelengths	of	 light	 further	 increase	 the	multiplexing	capacity	of	epigenome	
engineering	experiments.	The	spatial	and	temporal	specificity	afforded	by	optogenetics	can	
be	 used	 to	 direct	 sequential	 construction	 of	 complex	 regulatory	 architectures	 in	 a	 short	
window.			
	
	 While	genetic	models	have	provided	useful	 insights	into	the	function	of	 imprinting	
centres	 and	 the	 genes	 they	 regulate,	 a	 true	 exploration	 of	 the	 consequences	 of	 these	
epigenetic	 architectures	 requires	 tools	 targeted	 towards	 epigenetic	 modifications	
themselves.	 EpiEffectors	 provide	 a	 method	 of	 targeted	 epigenome	 editing,	 and	 several	
effective	 editors	 have	 already	 been	 published.	 These	 have	 so	 far	 focused	 on	 simple,	
fundamental,	 and	 useful	modifications,	 but	 there	 are	 still	 several	more	 configurations	 of	
components	already	at	hand	which	may	improve	our	capacity	to	construct	and	deconstruct	
more	 complex	 arrangements.	 Experimental	 designs	 using	 these	 tools	 can	 follow	 similar	
principles	 to	 genome	 engineering	 experiments,	 but	 must	 also	 acknowledge	 epigenome-
specific	 requirements:	 functional	 consequences	may	 be	 inferred	 from	 epigenome	 editing	
only	if	this	editing	is	heritable	across	mitotic	divisions	and	is	independent	from	changes	to	
the	genome	sequence.		
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Executive	Summary	
	
Conventional	Transgenic	Strategies	
● Conventional	genetic	manipulation	 is	 indirect	and	confounds	understanding	of	 the	
epigenetic	mark	independent	of	genomic	sequence.		
● Global	 manipulation	 of	 regulatory	 DNA	 methylation	 and	 histone	 marks	 by	
pharmacology	 or	 genetic	 knockout	 obscures	 functional	 consequences	 of	 specific,	
localized	imprinting	architecture	
Tools	for	Targeted	Epigenome	Editing	
● 	An	 EpiEffector,	 or	 epigenome	 engineering	 tool,	 is	 a	 programmable	 DNA	 binding	
domain	(DBD)	or	mechanism	coupled	to	an	epigenetic	effector	domain	
● CRISPR	based	tools	are	appealing	because	of	the	ease	and	multiplexing	capacity	of	
targeting	by	synthetic	guide	RNAs	(sgRNAs)	
● Simple	marks	 such	 as	 somatically	 heritable	 repressive	 DNA	methylation	 [32]	 and	
histone	3,	lysine	27	acetylation	(H3K27ac)	[33]	are	already	feasible		
Precise	Control	of	EpiEffector	Activity	
● Tissue-	 or	 stage-specific	 promoters,	 cre-lox	 systems,	 and	 optogenetic	 actuators	
[4,38-40]	 can	 add	 an	 additional	 layer	 of	 spatio-temporal	 precision	 to	 EpiEffector	
Activity		
Potential	Strategies		
● Ectopic	duplication	of	imprinting	architecture	
● Defining	critical	windows	for	changes	in	imprinting	marks	
● Rescue	of	imprinting	deficiency	
Potential	Tools	
● Methylation-sensitive	 EpiEffectors	 could	 make	 allele-specific	 regulatory	 changes	
based	on	existing	germline	ICRs	
● Using	multiple	systems,	such	as	CRISPR/Cas9,	Cpf1,	TALEs,	and	ZNFs	could	increase	
multiplexing	capacity	and	targeting	specificity	for	constructing	complex	architecture	
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